ArticleDiscover oncology2025
Immune cell dynamics and prognostic role of M2 macrophages and LDOC1 in colon adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon adenocarcinoma (COAD) is influenced by the tumor microenvironment, including immune cell dynamics, particularly M2 macrophages. Understanding these dynamics can offer insights into tumor progression and potential therapies.
methodsWe analyzed TCGA COAD data to quantify immune infiltration using TIMER, CIBERSORT, QUANTISEQ, MCPcounter, xCell, and EPIC methods. The ESTIMATE algorithm provided stromal and immune scores. WGCNA identified key gene modules correlated with immune infiltration. Prognostic significance of these genes was assessed using univariate Cox regression, Kaplan-Meier analysis, and nomogram construction. Single-cell RNA sequencing data from TISCH2 was used to explore gene expression correlations across cell types. We also examined correlations of LDOC1 with TMB, MSI, NEO, and tumor purity, and predicted immunotherapy responses using TIDE and Submap analyses. Drug sensitivity was analyzed using GDSC data.
resultsSignificant variations in M2 macrophage levels were found between tumor and normal tissues. WGCNA identified three key gene modules. Univariate Cox regression highlighted DMPK and LDOC1 as significant prognostic genes. Pan-cancer analysis showed LDOC1 as a crucial prognostic marker across various cancers, with strong correlations to multiple pathways. Single-cell analysis revealed distinct expression patterns of DMPK and LDOC1. In COAD, LDOC1 expression correlated significantly with immune checkpoints and tumor microenvironment scores. TIDE and Submap analyses suggested better immunotherapy response in low LDOC1 groups. Drug sensitivity analysis identified eight potential therapeutic agents.
conclusionThis study underscores the importance of M2 macrophages and LDOC1 in COAD, highlighting their potential as prognostic markers and therapeutic targets, paving the way for personalized treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.